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In immunotherapeutic research, over the last two decades, very intensive investiga-
tions were carried out of the preparation, experimental and clinical characteristics of a
relatively new category of active substances, the so-called immunostimulants. They are
products of natural or synthetic origin with different chemical characteristics and mecha-
nisms of action (1). Such an immunostimulating drug is Sterodin®. It is the proprietary
name of the medicine produced from bile lipids and bacterial metabolites from Staphylo-
coccus albus, Micrococcus catarrhal, E. coli, Paratyphoid A and B, Staphylococcus aureus, etc.
Each strain has a definite number of cells in each mL of solution. Sterodin® has been
claimed to possess a non-specific immunopotentiating activity, particularly in infectious
diseases. However, the mechanism of action and the exact parameters that are influenced
by Sterodin® are still unknown. Therefore, we performed some toxicological and phar-
macological evaluations to get some basic data about Sterodin®.
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Sterodin® is a novel non-specific immunostimulating drug
produced by a combination of bile lipids and bacterial
metabolites. In the present study, we investigated some
of its (i) toxicological and (ii) pharmacological properties
in vivo, and (iii) drug-lipid interaction (lipid peroxidation)
in vitro. We also evaluated the possible (iv) Sterodin®-in-
duced lipid peroxidation as well as the effect of ascorbic
acid on this peroxidation. We found LD50 of Sterodin®
to be 31.50 mL kg–1 body mass. In male albino mice,
Sterodin® increased the total white blood cells and neu-
trophils count by 59 and 26 %, respectively, on the 6th
day, compared to day 0 after injection and stimulated
phagocytic activity in vivo. We used goat liver as lipid
source in drug-lipid interaction studies in vitro. Our ex-
periments show that Sterodin® induces lipid peroxidation,
which was prevented by ascorbic acid.
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Drug-induced lipid peroxidation may be considered as a possible mechanism of
drug-induced toxicity. Lipid peroxidation is oxidative deterioration of polyunsaturated
lipids that occurs through a free radical mediated chain reaction (2). In case of a reduced
or impaired defense mechanism and excess generation of free radicals that are not coun-
terbalanced by endogenous antioxidant defense, exogenously administered antioxidants
have been proven useful in overcoming oxidative damage (3). The possible role of anti-
oxidants in reducing drug-induced lipid peroxidation provides a scope for considering
antioxidants as prospective candidates in therapy aimed at reducing drug-induced tox-
icity and consequently increasing the therapeutic index. Thus, besides toxicological and
pharmacological evaluation of Sterodin®, we also tried to find out whether Sterodin®
had a lipid peroxidation induction capacity. As ascorbic acid reduced drug-induced li-
pid peroxidation in our previous study (4), we also evaluated its antiperoxidative poten-
tial in experiments with Sterodin® in vitro.
EXPERIMENTAL
Materials
Some toxicological and pharmacological evaluations were made in vivo and the ex-
perimental protocol was approved by the Animal Ethical Committee of Union Drug
Company Ltd., India (under the guidelines of the Committee for the Purpose of Control
and Supervision of Experiments on Animals, Animal Welfare Division, Government of
India). In all in vivo experiments, normal healthy Swiss male albino mice weighing 17–22 g
were used. All the animals were housed under normal ambient temperature (25–29°C)
and acclimatized in the laboratory for at least 72 h. They were maintained at a standard
laboratory diet and water ad libitum. Drug-lipid interaction studies were performed in
vitro using goat liver as lipid source. Goat liver was selected because of its easy availabi-
lity and close similarity to human liver in its lipid profile (5). The liver was collected
from a Kolkata Municipal Corporation approved outlet.
Samples of Sterodin® were provided by Union Drugs Ltd., India. Ascorbic acid,
thiobarbituric acid (TBA) and trichloroacetic acid (TCA) were purchased from Ranbaxy
Fine Chemicals Ltd. India. 5,5’-Dithiobis-(2-nitrobenzoic acid) (DTNB) was purchased
from SRL Pvt. Ltd. India. 1,1,3,3-Tetraethoxypropane (TEP) and reduced glutathione were
obtained from Sigma Chemicals Co., USA. All other reagents were of analytical grade
and locally purchased.
Toxicological tests
Determination of acute toxicity of Sterodin® by the probit analysis method. – A pilot study
was conducted to select the dose ranges before perfoming the acute toxicity study. In the
pilot study, there were two groups of mice, of four animals each. In the acute toxicity
study, there were seven groups of ten male albino mice each.
The dose ranges of Sterodin® were 0.30, 0.40, 0.50, 0.60, 0.70, 0.80, 1.0 mL per 20 g of
body mass. All ten animals in a particular group received the same one dose of Stero-
din®. Lethality of Sterodin® was examined by injecting Sterodin® intraperitoneally into
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male albino mice. The percentage of mortality at different doses was calculated and the
values were transformed to the probit scale and LD50 was calculated after developing
the regression equation (6).
Test for undue toxicity of Sterodin®. – Safety test was done to determine compliance
with the requirements given in individual monographs/specifications. This test is in-
tended to detect any unexpected, unacceptable, biological reactivity in a substance. This
is an in vitro test designed for safety assessment of biologics and biotechnology derived
products.
Five male albino mice each received a single intravenous injection of 0.05 mL of 80 %
Sterodin® in water solution per 20 g b. m. The 80 % Sterodin® was injected over a period
of about 15–30 s. The substance passed the test if none of the animals died within 24
hours (7).
Evaluation of behavioral changes induced by Sterodin®. – The dose level without any
toxic symptoms was evaluated on four groups of mice of six animals each. All mice were
injected Sterodin® intraperitoneally at one of the following doses: 0.05, 0.10, 0.20, 0.40
mL per 20 g b. m. All animals in a particular group received the same one dose of
Sterodin®. Behavioral changes such as the righting reflex, rate of respiration, spasms,
convulsions, etc., were observed up to 4 hours.
Selected pharmacological tests
Total and differential white blood cell count (WBC). – Ten mice were taken for this ex-
periment. Sterodin® was injected intraperitoneally at a dose of 0.05 mL per 20 g b. m. All
ten animals received the same dose of Sterodin®. Blood was taken from the tail vein on
day 0, 6 and 30 days after the injection. Total WBC and differential white blood cell
count (neutrophils and lymphocytes) per cm3, respectively, were recorded using common
laboratory techniques in a haemocytometer chamber (8).
Carbon clearance test for in vivo phagocytosis. – Control and Sterodin® treated groups,
each comprising five animals were administred either 0.2 mL per 20 g b. m. of indian ink
(purchased in the form of i.v. injection from Rottring, Germany), intravenously only (con-
trol group), or 0.05 mL Sterodin® per 20 g b. m. intraperitoneally (Sterodin® treated
group) six days before and 30 minutes prior to the experiment. They also received intrave-
nous injection of 0.2 mL per 20 g b. m. of indian ink. Blood samples (20 µL) were with-
drawn from the retro orbital plexus of each mouse at 0, 0.5, 2, 5, 15 minutes from the be-
ginning of the experiment. Then 3 mL of distilled water was added to 20 µL of blood to
lyse the erythrocytes. At the end, absorbance of the mixed solution (20 µL blood in 3 mL
distilled water) was measured using a Shimadzu UV-1700 double beam spectrophotomet-
er (Japan) at 650 nm (9). The carbon clearance rate was expressed relative to the control at
respective points of time. The phagocytic index (PI) was calculated by deducing the ratio
of the slope of absorbance-time curve of Sterodin®-treated and control group, respectively.
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Drug lipid interaction studies
Preparation of tissue homogenate for lipid peroxidation studies. – Goat liver (collected
within a few minutes after the death of the animal) perfused with normal saline through
the hepatic portal vein was harvested and its lobes were briefly dried between filter pa-
pers to remove excess blood and then thinly cut with a heavy-duty blade. The small
pieces (5 mm2) were then transferred into a sterile vessel containing phosphate buffer
(pH 7.4) solution. After draining the buffer solution from the sterile vessel as completely
as possible, the liver was immediately ground to make a tissue homogenate (1 g L–1) us-
ing freshly prepared phosphate buffer (pH 7.4). The homogenate was divided into four
equal parts, which were then treated differently as mentioned below.
Incubation of tissue homogenate with Sterodin® and/or ascorbic acid. – One goat liver tis-
sue portion was kept as control (C) and another was treated with Sterodin® (S) (1.3 L
g–1 tissue homogenate). The third portion (SA) was treated with Sterodin® (1.3 L g–1
tissue homogenate) and ascorbic acid (1.874 x 10–7 mol g–1 tissue homogenate) and the
fourth was treated with ascorbic acid (A) alone (1.874 x 10–7 mol g–1 tissue homogenate).
After treatment with Sterodin® and/or ascorbic acid, each portion of liver homogenate
was shaken and incubated at 18 ± 2 °C for 24 hours for further processing. This tempera-
ture was found suitable for preservation of liver homogenate as well as for subsequent
experiments.
Estimation of lipid peroxidation in liver tissue homogenates (MDA). – The extent of lipid
peroxidation was measured in terms of MDA content using the thiobarbituric acid me-
thod (10). Estimation was made at 2, 4 and 24 hours of incubation time and was repeated
in five animal sets. In each case, three parallel samples of 2.5 mL of the incubation mix-
ture were treated with 2.5 mL of 10 % (m/V) trichloroacetic acid and centrifuged at room
temperature at 3000 rpm for 30 minutes to precipitate proteins. Then, 2.5 mL of the
supernatant was treated with 5 mL of 2 mmol L–1 TBA solutions and then the volume
was made up to 10 mL with distilled water. The mixture was heated on a boiling water
bath for 30 minutes. The tubes were cooled to room temperature and the absorbance
was measured at 530 nm against a TBA blank (prepared from 5 mL of TBA solution and
5 mL of distilled water). MDA concentration was determined from a standard curve.
Different aliquots of standard 1,1,3,3-tetrahydroxypropane (TEP) solution underwent
the same procedure as described above. The best-fit equation was A = 0.007171 c, where
c is concentration of MDA in nanomoles per 10 mL solution, A is absorbance (R = 0.993).
Estimation of lipid peroxidation in liver homogenates in terms of GSH content. – Reduced
glutathione (GSH) was measured by reaction with DTNB (11). Estimation was made at
2, 4 and 24 hours of incubation time and was repeated in five animal sets. In each case
three parallel samples of 1 mL of the incubation mixture were treated with 1 mL of 5 %
(m/V) TCA in 1 mmol L–1 EDTA and centrifuged at 2000 g for 10 minutes. After that, 1 mL
of the filtrate was mixed with 5 mL of 0.1 mol L–1 phosphate buffer (pH 8.0) and 0.4 mL of
0.01 % DTNB in phosphate buffer pH 8.0. Absorbances of the solutions were measured at
412 nm against a blank (prepared from 6.0 mL of phosphate buffer and 0.4 mL of DTNB)
(0.01 % in phosphate buffer). The concentration of reduced glutathione was determined
from a standard curve. The best-fit equation was A = 0.001487 c, where c is a concentration
of reduced glutathione in nanomoles per 10 mL solution, A is absorbance (R = 0.996).
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Changes in malondialdehyde and reduced glutathione levels of different samples
were expressed as average percent changes with respect to control values at the corre-
sponding hours of incubation along with the corresponding standard error of mean in
five sets. Interpretation of the results was supported by the paired-test and by analysis
of variance (ANOVA) (12).
RESULTS AND DISCUSSION
Toxicological tests
By probit analysis method (Fig. 1) it was found that, LD50 of Sterodin® injection was
0.63 mL per 20 g b. m. male albino mice (i.e., 31.50 mL kg–1 b. m.). The significance of the
regression equation is judged from R = 0.968; high F-value of 75.84 (Ftheor = 6.61) (df = 1, 5)
at p = 0.05 speaks on behalf of high variance between groups in respect to variance
within groups. In the toxicity study with 80 % STERODIN® injected intravenously none
of the animals died within 24 hours and therefore the substance passesed the test ac-
cording to USP 28 (7). The observations of sequential changes in behavioral pattern after
administration of Sterodin® indicate that therapeutic dose to mice of 0.03 to 0.06 mL per
20 g b. m. (intraperitoneally) of the drug did not show any behavioral changes in male
albino mice within 4 hours.
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Fig. 1. Estimation of LD50 of Sterodin® by probit analysis.
Regression equation:
Y = 6.51 + 7.58X (R = 0.968);
F = 75.84, Ftheor = 6.61 (df = 1, 5),
95 % confidence level.
Pharmacological tests
The results on the effect of Sterodin® on the total and differential white blood cell
counts are shown in Table I. The final results were expressed as a mean (cm3) with the
corresponding standard error of the mean. Maximum increase of 59 and 26 % in mean
total and differential white blood cell counts, respectively, was observed on the 6th day
after a single Sterodin® injection. After 30 days, the differential white blood cell count
came to nearly day 0 level/control value, which indicates that Sterodin® activity can be
retained at most for a month. The t-value was calculated by applying null hypothesis to
observe the variability among 10 animals in a particular group.
The results on the effect of Sterodin® on carbon particle clearance from the blood
are reported in Table II. Carbon clearance after 15 minutes of incubation suggested a sig-
nificant enhancement (43.2 % with respect to the control) in the phagocytic function of
the macrophages, and thus contributing to nonspecific immunity. The phagocytic index
of 1.314 indicates stimulation by Sterodin® of both the reticuloendothelial system and
the activity of macrophages. The two-tailed t-values (df = 4) in Table II indicate the pro-
nounced effects of Sterodin® on carbon clearance from 2 min onwards.
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10 0.05 0 5882 ± 181b 61 ± 1.5b 39 ± 1.5b
6 9345 ± 805b 77 ± 1.6b 23 ± 1.6b
30 6875 ± 190b 67 ± 2.04b 33 ± 2.04b
N, L – neutrophils and lymphocytes, respectively.
a Mean ± SEM (n = 10).
b Significant difference between animals in a group: p < 0.005.
Table II. Effect of Sterodin® injection on carbon clearance and the phagocytic index
Time (min)
Carbon clearance (%)
(t-value, df = 4)a
Phagocytic index
(PI)b





a Percent change with respect to control at respective time points. The two tail t-value at the p = 0.01 is 4.604
(df = 4).
b PI = K (Sterodin®-treated)/K (control), where K is the slope of regression line.
Drub-lipid interaction studies. – Incubation of the liver homogenates with Sterodin®
caused an increase in MDA content with respect to the control such as 8.6, 8.9 and 5.2 %
at 2, 4 and 24 hours of incubation, respectively (Table III). These observations suggest
that Sterodin® has the ability to induce the lipid peroxidation process. It was further
found that MDA content was significantly reduced, by –15.7, –15.9 and –10.2 % affter
different hours of incubations, when the liver tissue homogenate was treated with both
Sterodin® and ascorbic acid compared to the Sterodin®-treated group. This implies that
ascorbic acid could reduce the extent of Sterodin®-induced lipid peroxidation.
Threatment of the tissue homogenate with ascorbic acid only also increased the MDA
content with respect to the control at the 2nd hour of incubation (4.9 %). This implies the
pro-oxidant effect of ascorbic acid. It was postulated that ascorbic acid could reduce
Fe3+ to Fe2+, which promotes generation of hydroxyl radicals and other reactive oxygen
species through Fenton’s reaction (13). Many vitamins have been reported to act as
pro-oxidants in the presence of transition metals (14).
Incubation of the liver tissue homogenate with Sterodin® decreased the GSH level
with respect to the corresponding controls such as –10.9, –9.9 and –8.5 % after 2, 4 and 24
hours of incubation, resp. (Table IV). Depletion of the GSH content was associated with
an increase in lipid peroxidation. The decreased GSH level may be a consequence of en-
hanced utilization of this compound by the antioxidant enzymes glutathione peroxidase
and glutathione-S-transferase. When the tissue homogenate was treated both with
Sterodin® and ascorbic acid, the GSH level increased in comparison with the
Sterodin®-treated group by 22.0, 19.5 and 22.8 % at different hours of incubation. Incuba-
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Table III. Effects of ascorbic acid on Sterodin®-induced lipid peroxidation: changes in MDA content







Two tail t-value at
p = 0.05 (df = 4)
Calcd. Theor.
2 S 8.6 ± 2.5 F1 = 32.34 (df = 2, 8)
F2 = 0.05 (df = 4, 8)
3.10 2.776
SA –15.7 ± 2.1 6.29 2.776
A 4.9 ± 0.4 8.13 2.776
4 S 8.9 ± 2.1 F1 = 30.86 (df = 2, 8)
F2 = 0.404 (df = 4, 8)
3.80 2.776
SA –15.9 ± 1.1 9.55 2.776
A –5.9 ± 2.6 2.14 2.776
24 S 5.2 ± 0.9 F1 = 21.65 (df = 2, 8)
F2 = 1.44 (df = (4, 8)
3.42 2.776
SA –10.2 ± 2.0 9.71 2.776
A –10.3 ± 2.8 3.21 2.776
a S, SA, A – Sterodin®-treated, Sterodin® and ascorbic acid-treated, ascorbic acid-treated liver tissue homogenate
b With respect to corresponding control; mean ± SEM, n = 5.
c Theoretical values of F: p = 0.05 F1 = 4.46 (df = 2, 8), F2 = 3.84 (df = 4, 8), p = 0.01 F1 = 8.65 (df = 2, 8), F2 = 7.01
(df = 4, 8), F1 and F2 corresponding to variance ratio between groups and within groups, respectively.
tion of tissue homogenates with ascorbic acid only also enhanced the GSH level by 7.7,
10.0 and 14.3 % after different hours of incubation suggesting that increase in the GSH
level may be due to the antioxidant property of ascorbic acid.
In both MDA and GSH estimations, there are significant differences (F1) among
groups, such as Sterodin®-treated, Sterodin® plus ascorbic acid-treated as well as only
ascorbic acid-treated group, but differences within a particular group (F2) are not signifi-
cant, which shows that there is no statistical difference in goat liver obtained from differ-
ent animal sets. The calculated t-values for the above mentioned groups with respect to
the corresponding controls at specific times of incubation are higher than the theoretical
value pointing to the fact that pharmacological effects have taken place in those groups
(Tables III and IV).
CONCLUSIONS
Sterodin®, composed of bacterial metabolites and bile lipids, has been claimed to
possess immunopotentiating activity, particularly in infectious diseases. The experimen-
tal data reported here indicates that Sterodin® increased the total WBC count, neutro-
phils count and stimulated the phagocytic activity in vivo. All of these effects can in-
crease the efficacy of the immune system. Our findings of drug-lipid interaction studies
suggest that ascorbic acid prevented lipid peroxidation induced by Sterodin®. The con-
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Two tail t-value at
p = 0.05 (df = 4)
Calcd. Theor.
2 S –10.9 ± 1.2 F1 = 71.68 (df = 2, 8)
F2 = 1.55 (df = 4, 8)
7.999 2.776
SA 22.0 ± 2.8 13.90 2.776
A 7.7 ± 2.4 8.467 2.776
4 S –9.9 ± 1.5 F1 = 53.68 (df = 2, 8)
F2 = 0.785 (df = 4, 8)
8.246 2.776
SA 19.5 ± 2.5 9.238 2.776
A 10.0 ± 1.8 6.664 2.776
24 S –8.5 ± 1.1 F1 = 71.15 (df = 2, 8)
F2 = 1.65 (df = 4, 8)
6.501 2.776
SA 22.8 ± 3.2 23.79 2.776
A 14.3 ± 1.4 15.44 2.776
a S, SA, A – Sterodin®-treated, Sterodin® and ascorbic acid-treated, only ascorbic acid-treated liver tissue
homogenate
b With respect to the corresponding control; mean ± SEM (n = 5).
c Theoretical values of F: p = 0.05 F1 = 4.46 (df = 2, 8), F2 = 3.84 (df = 4, 8), p = 0.01 F1 = 8.65 (df = 2, 8), F2 = 7.01
(df = 4, 8). F1 and F2 corresponding to variance ratio between groups and within groups, respectively.
cept of antioxidant co-therapy may also be exploited in the future formulation design of
drugs to reduce drug-induced toxicity. However, further extensive study is required to
advance this hypothesis.
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S A @ E T A K
Sterodin®, novi imunostimulator: neka toksikolo{ka i farmakolo{ka
vrednovanja in vivo i interakcija lijek-lipid in vitro
SARBANI DEY RAY, PARTHA PRATIM ROY i SUPRATIM RAY
Sterodin je novi nespecifi~ni imunostimulator koji sadr`i `u~ne lipide i bakterijske
metabolite. U radu su opisana neka njegova toksikolo{ka i farmakolo{ka svojstva in vivo,
te interakcija lijek-lipid in vitro. Nadalje, prou~avana je mogu}a peroksidacija lipida in-
ducirana Sterodinom te u~inak askorbinske kiseline na tu peroksidaciju. LD50 Sterodi-
na bio je 0,63 mL u mu`jacima albino mi{eva mase 20 g (31,50 mL kg–1 tjelesne mase).
U istim `ivotinjama Sterodin je pove}ao ukupan broj leukocita i neutrofila (59 odnosno
26 % mjereno 6 dana nakon injekcije Sterodina) i stimulirao aktivnost fagocita in vivo.
U ispitivanjima interakcije lijek-lipid in vitro kori{tena je jetra koze kao izvor lipida. Re-
zultati ukazuju da Sterodin inducira peroksidaciju lipida, koja se mo`e sprije~iti askor-
binskom kiselinom.
Klju~ne rije~i: Sterodin, imunostimulator, askorbinska kiselina, peroksidacija lipida, malondialde-
hid, reducirani glutation
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